Essential Hypertension & Hypertensive Urgency/Emergency Management

Essential Hypertension & Hypertensive Urgency/Emergency Management

Pathophysiology and Hemodynamic Determinants

Hypertension (HTN) is the primary modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, stroke, and chronic kidney disease (CKD). Blood pressure is determined by the relationship: Blood Pressure = Cardiac Output (CO) x Systemic Vascular Resistance (SVR). In young adults, hypertension is frequently driven by increased cardiac output associated with hyperdynamic sympathetic tone. In older adults, hypertension is primarily driven by arterial stiffening, loss of vascular elasticity, and structural vascular remodeling, resulting in elevated SVR and isolated systolic hypertension.

The renin-angiotensin-aldosterone system (RAAS) regulates long-term blood pressure and renal hemodynamics. Angiotensinogen is converted by renin (released by juxtaglomerular cells in response to reduced renal perfusion) into angiotensin I, which is converted to angiotensin II by angiotensin-converting enzyme (ACE) in the pulmonary endothelium. Angiotensin II causes direct arterial vasoconstriction and stimulates adrenal aldosterone secretion, promoting renal sodium and water reabsorption while enhancing potassium excretion. Overactivation of RAAS causes persistent arterial vasoconstriction, volume expansion, and target organ damage.

ACC/AHA Blood Pressure Classification and Measurement Standards

Accurate blood pressure measurement requires standardized in-office protocols. Patients must sit quietly for 5 minutes before measurement, with back supported and feet flat on the floor. The arm must be supported at heart level; taking BP on an unsupported arm falsely elevates systolic pressure by 2-10 mmHg. The cuff bladder must encircle at least 80% of upper arm circumference. Patients should avoid caffeine, exercise, and smoking for 30 minutes prior. Diagnosing hypertension requires an average of two or more properly measured readings over separate clinical encounters.

Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM) is recommended to confirm diagnosis and rule out white-coat hypertension (elevated in-office BP but normal out-of-office BP) or masked hypertension (normal in-office BP but elevated out-of-office BP).

First-Line Pharmacotherapy and Demographic Preferences

Target blood pressure for most adults, including those with established ASCVD, diabetes, CKD, or 10-year ASCVD risk >=10%, is <130/80 mmHg. Lifestyle modifications (DASH diet, sodium restriction <1,500-2,300 mg/day, weight loss, exercise 150 min/week, limiting alcohol) are indicated for all patients.

First-line antihypertensive agents for uncomplicated hypertension belong to three major classes:

1. Thiazide/Thiazide-like Diuretics: Chlorthalidone (12.5-25 mg daily) and indapamide are preferred over Hydrochlorothiazide (HCTZ) due to longer half-lives (40-60 hours vs. 6-12 hours) and superior reduction in ASCVD events. Adverse effects include hyponatremia, hypokalemia, hyperuricemia (gout), and hyperglycemia.
2. Calcium Channel Blockers (CCBs): Dihydropyridine CCBs (amlodipine 5-10 mg daily, nifedipine ER) induce arteriolar smooth muscle relaxation and vasodilation. Dose-dependent peripheral edema is common; combining a CCB with an ACE inhibitor or ARB reduces edema. Non-dihydropyridines (diltiazem, verapamil) exert negative inotropic effects and are avoided in HFrEF.
3. ACE Inhibitors and ARBs: ACE inhibitors (lisinopril, enalapril) prevent conversion of angiotensin I to II, while ARBs (losartan, valsartan) block AT1 receptors. Both classes reduce SVR and provide renal microvascular protection. ACE inhibitor side effects include dry cough (bradykinin accumulation) and angioedema. ARBs do not affect bradykinin and are preferred if cough occurs. Both cause hyperkalemia and modest serum creatinine elevations (up to 30% rise is acceptable). Both are strictly contraindicated in pregnancy due to fetal toxicity.

Demographic Preferences: In Black adults without chronic kidney disease, initial therapy should consist of a dihydropyridine CCB or thiazide diuretic. Black patients demonstrate greater blood pressure reduction and stroke prevention with CCBs and thiazides compared to ACE inhibitors or ARBs as monotherapy.

Compelling Indications and Secondary Hypertension

Compelling comorbid conditions dictate drug selection regardless of race:

• CKD with Albuminuria: In patients with CKD (eGFR <60 mL/min/1.73 m²) or diabetes with persistent albuminuria (UACR >=30 mg/g), an ACE inhibitor or ARB is mandatory first-line therapy to reduce intraglomerular pressure and slow kidney disease progression.
• Post-MI and HFrEF: Patients with prior MI or HFrEF require an ACE inhibitor/ARB (or ARNI) plus an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol).
• Stroke History: A thiazide diuretic plus ACE inhibitor is recommended post-stroke.

Secondary hypertension accounts for 5-10% of cases and should be evaluated in abrupt onset, age <30 or >55, or resistant cases:

• Renal Artery Stenosis: Suspect in older adults with progressive vascular disease or young females with fibromuscular dysplasia (abdominal bruit or acute >30% rise in creatinine on ACEi/ARB).
• Primary Aldosteronism: Suggested by resistant HTN with unprovoked hypokalemia (plasma aldosterone-to-renin ratio ARR >20).
• Obstructive Sleep Apnea (OSA): Common in obese patients with snoring, fatigue, and resistant HTN.

Resistant Hypertension is defined as BP above target despite adherence to 3 optimal-dose agents of different classes, including a diuretic. Management includes ruling out pseudo-resistance, stopping interfering agents (NSAIDs, decongestants), and adding Spironolactone (12.5-25 mg daily) as fourth-line agent (provided K+ <5.0 mEq/L and eGFR >=30 mL/min/1.73 m²).

Hypertensive Crises: Urgency vs. Emergency Management

Hypertensive crisis is defined as severe acute BP elevation, typically SBP >180 mmHg and/or DBP >120 mmHg.

• Hypertensive Urgency: SBP >180 mmHg and/or DBP >120 mmHg WITHOUT acute target organ damage. Managed with oral antihypertensives (labetalol, captopril, clonidine) over 24 to 48 hours in outpatient settings. Rapid BP lowering must be avoided to prevent ischemic stroke or MI.
• Hypertensive Emergency: SBP >180 mmHg and/or DBP >120 mmHg WITH acute target organ damage (encephalopathy, stroke, acute coronary syndrome, acute pulmonary edema, aortic dissection, acute renal failure, papilledema). Requires immediate ICU admission and continuous IV infusions (nicardipine, clevidipine, labetalol, esmolol).

BP Lowering Goals in Emergency: Reduce SBP by maximum 25% within 1st hour; then to 160/100 mmHg over 2 to 6 hours, cautiously normalizing over 24 to 48 hours. Clinical Exceptions:

1. Aortic Dissection: Rapidly lower SBP to <120 mmHg within 20 minutes (with IV beta-blockers targeting HR <60 bpm).
2. Acute Ischemic Stroke: Do not lower BP unless SBP >220 mmHg or DBP >120 mmHg, UNLESS eligible for thrombolysis (target <185/110 mmHg before tPA).

Geriatric Considerations

In older adults, screen routinely for orthostatic hypotension (drop in SBP >=20 mmHg or DBP >=10 mmHg within 3 minutes of standing). According to the 2023 AGS Beers Criteria, central alpha-2 agonists (clonidine) and alpha-1 blockers (doxazosin, terazosin) should be avoided for routine HTN management due to high risks of CNS depression, severe orthostatic hypotension, and falls.